Summary
Cencora, Inc. (COR) reported strong revenue growth in the fourth quarter of fiscal year 2023, driven by a significant 15.9% increase in its U.S. Healthcare Solutions segment, bolstered by higher unit volumes, particularly in GLP-1 class drugs for diabetes and weight loss, specialty products, and COVID-19 vaccines. International Healthcare Solutions also saw a respectable 6.9% revenue increase, benefiting from growth in its European, Canadian, and Brazilian businesses, as well as the recent PharmaLex acquisition. Profitability saw a substantial improvement, with gross profit up 15.0% year-over-year, aided by increased sales and a favorable LIFO credit compared to an expense in the prior year. Operating income also saw a significant 30.0% increase, reflecting disciplined expense management and operating leverage from revenue growth. While the company continues to navigate significant opioid litigation accruals, a notable reduction in the opioid litigation settlement accrual due to a prepay significantly benefited current quarter results. The company also repurchased $385.5 million in common stock and increased its quarterly dividend, signaling confidence in its financial position and commitment to returning value to shareholders.
Financial Highlights
55 data points| Revenue | $72.25B |
| Cost of Revenue | $69.78B |
| Gross Profit | $2.47B |
| SG&A Expenses | $1.40B |
| Operating Income | $822.88M |
| Net Income | $601.50M |
| EPS (Basic) | $3.01 |
| EPS (Diluted) | $2.98 |
| Shares Outstanding (Basic) | 200.08M |
| Shares Outstanding (Diluted) | 201.84M |
Key Highlights
- 1Revenue increased by 15.0% to $72.3 billion year-over-year, primarily driven by the U.S. Healthcare Solutions segment's 15.9% growth.
- 2GLP-1 class drug sales contributed significantly to revenue growth, with an increase of $2.1 billion.
- 3Gross profit rose by 15.0% to $2.47 billion, supported by increased sales and a favorable LIFO credit.
- 4Operating income saw a robust increase of 30.0% to $822.9 million, driven by both segment growth and improved operating leverage.
- 5The company recorded a $92.2 million reduction in its opioid litigation settlement accrual due to a prepayment, positively impacting net income.
- 6Cencora repurchased $385.5 million of its common stock during the quarter, with $423.5 million remaining under its repurchase program.
- 7The quarterly dividend was increased by 5% to $0.51 per share.